RE:RE:Fast Track + PR (CR) = Accelerated ApprovalAs previously posted .... The possibility of having an accelerated approval granted on the basis of the Phase 2 Goblet study, the results in pancreatic cancer and the results of the Bracelet-1 clinical trial are the reasons that I would strongly urge ONCY to pursue an accelaerated approval with the FDA - which would subsequently be followed up with a post-marketing confirmatory study in 2023. Other Big Pharma companies have been granted similar approvals for their I/O products on lesser results.